ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1555

An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients

Vibeke Strand1, Jenny Griffith2, Keith Betts3, Alan Friedman2, James Signorovitch3 and Arijit Ganguli2,4, 1Stanford University, Palo Alto, CA, 2AbbVie, Inc., North Chicago, IL, 3Analysis Group, Inc., Boston, MA, 4AbbVie Inc., North Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologics, comparative effectiveness and harms and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Apremilast (APR), a small molecule inhibitor of phospodiesterase 4 (PDE-4), was recently approved for treating PsA patients in the US. To date, there are no studies directly comparing APR to the current standard of care, MTX. This analysis compared the cost per responder for APR versus MTX and adalimumab (ADA) (a TNF inhibitor) from a US perspective.

Methods: A systematic literature review was performed to extract response rates from clinical trials of approved biologics, MTX, and APR. The selected clinical trials were required to be in the MTX-naïve PsA population and have a placebo arm. A subanalysis of the ADEPT trial, a phase 3 trial comparing ADA with placebo, was conducted among patients who did not receive MTX in the 3 month baseline period. Using Bayesian methods, a network meta-analysis was conducted to indirectly compare the efficacy outcomes between approved therapies for PsA at week 16. Based on the response outcomes relative to placebo, the number needed to treat (NNT) was calculated using the inverse of absolute risk reduction. Cost of treatment was defined as the cost of drug (wholesale acquisition cost) required to treat patients for 16 weeks per labelled dose and cost for placebo was assumed to be zero. The incremental cost per responder was calculated by multiplying the cost of treatment and NNT for each of the therapies.

Results: The MIPA1 trial for MTX, PALACE 42 for APR and the ADEPT subpopulation for ADA were the only clinical trials that met inclusion criteria. ACR20 was the common clinical outcome among the trials and was reported at week 16 for both ADA in ADEPT and APR in PALACE4, while week 24 results were reported for MTX in MIPA.  In the absence of week 16 efficacy data for MTX, efficacy at week 24 was assumed to be similar at week 16 for this analysis, conservatively. Upon analysis, the NNTs for MTX, APR and ADA were 8.31, 6.69 and 2.63, respectively, and the 16 weeks drug costs were $436, $6,844 and $10,010, respectively. The cost per ACR20 responder was $3,622 for MTX, $45,808 for APR and $26,316 for ADA.

Conclusion: Among MTX-naïve PsA patients, ADA had the lowest NNT compared with MTX and APR at week 16. Compared with MTX and ADA, APR had the highest cost per responder estimates among MTX-naïve PsA patients at week 16.

 

Reference:

1.       Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 2012;51:1368-77.

2.       Wells AF, et al. Apremilast in the treatment of DMARD-naïve psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4). Presented at ACR 2013.

**At the upper limit there is no incremental benefit


Disclosure:

V. Strand,

AbbVie, Afferent, Amgen, Biogen Idec, Bioventus, BMS, Carbylan, Celgene, Celltrion, CORRONA, Crescendo, Genentech/Roche, GSK, Hospira, Iroko, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, SKK, Takeda, UCB, Vertex,

5,

Up to Date,

7;

J. Griffith,

AbbVie, Inc.,

3,

AbbVie, Inc.,

1;

K. Betts,

Analysis Group, Inc.,

3;

A. Friedman,

AbbVie, Inc.,

1,

AbbVie, Inc.,

3;

J. Signorovitch,

Analysis Group, Inc. ,

3;

A. Ganguli,

AbbVie,

1,

AbbVie,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-indirect-comparison-and-cost-per-responder-analysis-of-adalimumab-methotrexate-mtx-and-apremilast-in-the-treatment-of-mtx-naive-psoriatic-arthritis-psa-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology